The PPAR family emerges to be a neoteric, propitious, and prospective target which holds the aptitude to assist in the therapy of neurodegenerative diseases, namely PD [31,58], Alzheimer’s disease (AD) [31,59], Huntington’s disease (HD) [31,60], Amyotrophic lateral sclerosis (ALS) [31,60], and Multiple sclerosis (MS) [61]. This evidence concerns the gene PPARA and Parkinson disease.